GSK plc (NYSE:GSK) has announced its plans to spend £1 billion over the next ten years on R&D focused on infectious diseases that disproportionately affect lower-income countries.
Diseases covered in the research will include malaria, tuberculosis, HIV, neglected tropical diseases (NTDs) and antimicrobial resistance (AMR).
The HIV focus will be through ViiV Healthcare, a joint venture involving GSK, Pfizer and Shionogi.
The R&D initiative will have a “ring-fenced” budget, with results gauged by their impact on health rather than profit, Thomas Breuer, GSK’s chief global health officer, told Bloomberg.
“I am delighted to renew our commitment to global health research for the coming decade, consistent with our purpose to unite our science, technology, and talent to get ahead of disease together and our ambition to deliver health impact at scale,” said Thomas Breuer, GSK chief global health officer, in a news release.
Last year, GSK re…